Drug Profile


Alternative Names: IBPM002BZ; IBPM002BZ (biosimilar) - Inbiopro Solutions

Latest Information Update: 15 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inbiopro Solutions
  • Class Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Colorectal cancer; Renal cell carcinoma; Small cell lung cancer

Most Recent Events

  • 31 Dec 2012 Clinical trials in Colorectal cancer (metastatic disease) in India (Parenteral) before December 2012
  • 31 Dec 2012 Clinical trials in Renal cell carcinoma (metastatic disease) in India (Parenteral) before December 2012
  • 31 Dec 2012 Clinical trials in Small cell lung cancer in India (Parenteral) before December 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top